Published in Neurology on November 01, 1990
Transient sixth-nerve palsy as the first presentation of acute leukaemia. J Neurol Neurosurg Psychiatry (1994) 0.78
Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM (1996) 2.54
Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N Engl J Med (1991) 2.05
Superficial hemosiderosis of the central nervous system. Mov Disord (1994) 1.66
Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet (1975) 1.66
Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis. Clin Exp Immunol (1975) 1.59
In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest (1988) 1.57
Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma. Neurology (1998) 1.50
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol (1993) 1.48
Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol (1998) 1.46
High frequency of hemorrhagic strokes in Jerusalem during the Persian Gulf War. Neurology (1992) 1.43
Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. Nature (1975) 1.43
An association between multiple sclerosis and type I diabetes mellitus. J Neurol (1992) 1.42
Halothane modifies ischemia-associated injury to the voltage-sensitive calcium channels in canine heart sarcolemma. Anesthesiology (1994) 1.41
Feto-feto-fetal transfusion syndrome in monozygotic monochorionic triamniotic triplets: vascular evaluation by a cast model. Placenta (2005) 1.40
Lack of hemispheric localizing value of the palmomental reflex. Neurology (2005) 1.40
Serum Cu/Zn superoxide dismutase activity is reduced in sporadic amyotrophic lateral sclerosis patients. J Neurol Sci (1996) 1.38
Antibiotic induced meningitis. J Neurol Neurosurg Psychiatry (1994) 1.33
Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol (1997) 1.22
Acute and chronic demyelinating inflammatory polyradiculoneuropathy. Association with autoimmune diseases and lymphocyte response to human neuritogenic protein. Arch Neurol (1986) 1.20
Antibodies to oligodendroglia in patients with multiple sclerosis. N Engl J Med (1977) 1.20
Inosiplex in the treatment of subacute sclerosing panencephalitis. Arch Neurol (1979) 1.16
Activity of multiple sclerosis during pregnancy and puerperium. Ann Neurol (1984) 1.16
Guillain-Barré syndrome after epidural anesthesia: direct nerve root damage may trigger disease. Neurology (1985) 1.16
Recurrence of acute disseminated encephalomyelitis at the previously affected brain site. Arch Neurol (2001) 1.13
Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J Clin Invest (1991) 1.10
Passive transfer of experimental autoimmune myasthenia by lymph node cells in inbred guinea pigs. J Exp Med (1975) 1.10
Radioimmunoassay of antibodies to acetylcholine receptor in serum of myasthenia gravis patients. Isr J Med Sci (1978) 1.09
Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals. Eur J Immunol (1994) 1.08
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler (2010) 1.07
Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol (1999) 1.06
Immunological relationship between acetylcholine receptor and thymus: a possible significance in myasthenia gravis. Proc Natl Acad Sci U S A (1975) 1.03
HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch Neurol (1999) 1.02
Hemiballismus: detection of focal hemorrhage in subthalamic nucleus by CT scan. Ann Neurol (1978) 1.02
Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor. Arch Neurol (1975) 1.01
Association of MS with thyroid disorders. Neurology (1999) 1.01
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A (1993) 1.00
Regulated expression of proenkephalin A in normal lymphocytes. J Immunol (1989) 0.99
Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther (1983) 0.99
Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol (2001) 0.99
Ictal hemiparesis. Eur Neurol (1982) 0.98
Sensory peripheral neuropathy of vitamin B12 deficiency: a primary demyelinating disease? J Neurol (1988) 0.98
Neurologic manifestations of progressive systemic sclerosis. Arch Neurol (1992) 0.98
Physiology of MPTP tremor. Mov Disord (1998) 0.97
Hereditary branching enzyme dysfunction in adult polyglucosan body disease: a possible metabolic cause in two patients. Ann Neurol (1991) 0.96
Hemianopic colour blindness. J Neurol Neurosurg Psychiatry (1975) 0.96
Reversible central nervous system dysfunction in folate deficiency. J Neurol Sci (1975) 0.96
Tetrabenazine induces acute dystonic reactions. Ann Neurol (1985) 0.95
Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest (1993) 0.95
Unsatisfactory treatment of acquired nystagmus with retrobulbar injection of botulinum toxin. Am J Ophthalmol (1995) 0.95
Introducing a novel approach of network oriented analysis of ERPs, demonstrated on adult attention deficit hyperactivity disorder. Clin Neurophysiol (2012) 0.95
A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol (1998) 0.95
Neurological features as presenting manifestations of brucellosis. Eur Neurol (1977) 0.95
Electrophysiological examinations of the visual system in multiple sclerosis. J Neurol Sci (1973) 0.94
Treatment and prevention of acute hepatic encephalopathy by intravenous levodopa. Surgery (1974) 0.94
Cytokeratin expression in human thymus: immunohistochemical mapping. Cell Tissue Res (1995) 0.94
Cognitive dysfunction following thalamic stroke: a study of 16 cases and review of the literature. J Neurol Sci (2000) 0.93
Parkinsonism and hyperthyroidism. Eur Neurol (1974) 0.93
Ampicillin may aggravate clinical and experimental myasthenia gravis. Arch Neurol (1986) 0.93
Chronic subdural hematoma simulating transient cerebral ischemic attacks. Case report. J Neurosurg (1975) 0.93
Serotonergic and noradrenergic receptors in the rat brain: modulation by chronic exposure to ovarian hormones. Life Sci (1983) 0.91
Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol (1992) 0.91
Stimulation of tumor necrosis factor-alpha production by mycoplasmas and inhibition by dexamethasone in cultured astrocytes. Brain Res (1993) 0.91
Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler (2003) 0.90
Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology (1996) 0.90
Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis. J Neuroimmunol (1994) 0.90
3-O-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol (1982) 0.90
Antiacetylcholine receptor antibody in neonatal myasthenia gravis. Am J Dis Child (1981) 0.89
Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. Eur J Clin Pharmacol (1984) 0.89
The effects of dextran sulfate, heparin and PGE1 on adenylate cyclase activity and aggregation of human platelets. Thromb Res (1979) 0.89
Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis. Proc Natl Acad Sci U S A (1996) 0.89
Modulation of high-frequency vestibuloocular reflex during visual tracking in humans. J Neurophysiol (1995) 0.89
Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders. Muscle Nerve (1995) 0.88
Treatment of acute hepatic encephalopathy with L-dopa. Postgrad Med J (1977) 0.88
Comparison of horizontal, vertical and diagonal smooth pursuit eye movements in normal human subjects. Vision Res (1996) 0.88
Cell-mediated immunity to neural antigens in idiopathic polyneuritis and myeloradiculitis. Clinical-immunologic classification of several autoimmune demyelinating disorders. Neurology (1975) 0.88
Neurologic manifestations in patients with mixed cryoglobulinemia. Neurology (1974) 0.88
Suppressive effect of pregnancy on the development of experimental allergic encephalomyelitis in rabbits. Am J Reprod Immunol (1984) 0.87
Associative visual agnosia without alexia. Neurology (1975) 0.87
Neuritogenic and encephalitogenic properties of the peripheral nerve basic proteins. J Neuropathol Exp Neurol (1975) 0.87
Appearance of Guillain-Barré syndrome in patients during corticosteroid treatment. J Neurol (1986) 0.86
Modulation of adenylate cyclase activity by sulfated glycosaminoglycans. II. Effects of mucopolysaccharides and dextran sulfate on the activity of adenylate cyclase derived from various tissues. Biochim Biophys Acta (1978) 0.86
Acetoacetate and D-(-)-beta-hydroxybutyrate as precursors for sterol synthesis by calf oligodendrocytes in suspension culture: extramitochondrial pathway for acetoacetate metabolism. J Neurochem (1979) 0.86
Primary pontine hemorrhage with complete recovery. Arch Neurol (1981) 0.86
Lack of apolipoprotein-E exacerbates experimental allergic encephalomyelitis. Mult Scler (2003) 0.86
Hypertrophic spinal pachymeningitis: report of two cases and review of the literature. Neurosurgery (1991) 0.86
Expression of alpha-smooth muscle actin in murine bone marrow stromal cells. Blood (1991) 0.86
Evaluation of the effect of stress on the blood--brain barrier: critical role of the brain perfusion time. Brain Res (2001) 0.85
Saccades to remembered targets: the effects of smooth pursuit and illusory stimulus motion. J Neurophysiol (1996) 0.85
Antibodies to galactocerebroside bind to oligodendroglia in suspension culture. J Neurol Sci (1979) 0.85
Aseptic meningitis as complication of intravenous immunoglobulin therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry (1993) 0.85
Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation. Mult Scler (1999) 0.84
Cerebral dominance for consciousness. Arch Neurol (1976) 0.84
Myasthenia gravis in the elderly. J Am Geriatr Soc (1976) 0.84
The effect of chronic L-dopa administration on supersensitive pre- and postsynaptic dopaminergic receptors in rat brain. Life Sci (1982) 0.84
Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT). Clin Exp Immunol (1995) 0.84
Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J Neuroimmunol (1994) 0.84
Changes in lymphocyte subsets in myasthenia gravis: correlation with level of antibodies to acetylcholine receptor and age of patient. Neurology (1992) 0.83
Adult-onset Niemann-Pick type C disease. Clinical, biochemical, and genetic study. Arch Neurol (1997) 0.83
In vitro synthesis of antibodies to acetylcholine receptor by Epstein-Barr virus-stimulated B-lymphocytes derived from patients with myasthenia gravis. J Neuroimmunol (1989) 0.83